Category:1930 births
Category:1989 deaths
Category:Corporate strategy
Category:Business theorists
Category:20th-century Russian businesspeople
Category:20th-century economists
Category:Moscow Institute of Steel and AlloysUsefulness of a drug-eluting stent as treatment for chronic total occlusion lesions in coronary artery bypass graft surgery patients.
Drug-eluting stents (DES) have emerged as a promising technology for the treatment of coronary artery disease. However, data on the efficacy of DES for chronic total occlusion (CTO) lesions are lacking. We evaluated the efficacy of DES for the treatment of CTO lesions after coronary artery bypass grafting (CABG). A total of 108 patients who underwent CABG and had a CTO lesion with a stent diameter of ≥3.0 mm and a total occlusion length of ≥40 mm were enrolled. CABG was performed through the CTO lesion with the use of DES (DES group; 54 patients) or bare-metal stents (BMS group; 54 patients). We compared clinical and angiographic outcomes of DES and BMS. Among the 54 DES patients, 55.6% were diabetic and 57.4% had prior myocardial infarction. After a median follow-up of 12 months, clinical outcomes were similar between the 2 groups. Late loss of minimal lumen diameter of the CTO lesion after DES was significantly lower than that of BMS at 6 months (1.1±0.9 vs. 2.0±1.3 mm; P=0.002), at 12 months (0.8±0.8 vs. 1.6±1.2 mm; P=0.001), and at 18 months (0.8±0.8 vs. 1.4±1.0 mm; P=0.004). At 18 months, the frequency of target lesion revascularization was significantly higher in the BMS group than the DES group (P=0.014). The DES group had a higher cumulative stent thrombosis rate compared with the BMS group (0.9% vs. 5.6%, P=0.042). The DES group also had a higher event-free survival rate than the BMS group (79.6% vs. 57.9%; P=0.037). DES is an acceptable treatment option for the treatment of CTO lesions ac619d1d87
Related links: